advertisement

ReliF

60 %
40 %
advertisement
Information about ReliF
Health & Medicine

Published on February 23, 2009

Author: allPowerde

Source: slideshare.net

Description

This was our presentation for our imaginary product for the commercialization workshop. Note, all "research results" and illustrations are totally made up and and therefore not necessarily reflecting reality (== biological processes). This presentation was created as part of the learning experience of how to pitch biological research to venture capitalists.
advertisement

Relif ® Feel the relief Dr. Denis C. Bauer CEO Prof. Dr. Cho l Hee Jung CSO Dr. Andrew Ringsmuth Business Development Manager Dr. Kimberly Wadsworth IP Manager

Introduction Currently,1.3 Million people suffer from acute depression. Estimated to increase exponentially within 10 years. Don Monger : “Depression will be the major impact on modern society” On the Threshold of Eternity by Vincent Van Gogh What if depression can be reduced to a small inconvenience - like headache?

Currently,1.3 Million people suffer from acute depression.

Estimated to increase exponentially within 10 years.

Don Monger : “Depression will be the major impact on modern society”

Overview Drug development Prof. Dr. Chol Hee Jung Scientific Overview Science behind the reliF ® approach Motivation and Progress Market analysis Financial overview IP portfolio Pitch

Drug development Prof. Dr. Chol Hee Jung

Scientific Overview

Science behind the reliF ® approach

Motivation and Progress

Market analysis

Financial overview

IP portfolio

Pitch

Serotonin messaging Pre-synaptic neuron : releases serotonin Post-synaptic neuron : recognizes serotonin with 5-HRR and relays the signal. In healthy individuals, about 90% of serotonin released into the synaptic cleft is re-absorbed into pre-synaptic neurons with only 10% bound to post-synaptic neurons.

Pre-synaptic neuron : releases serotonin

Post-synaptic neuron : recognizes serotonin with 5-HRR and relays the signal.

In healthy individuals, about 90% of serotonin released into the synaptic cleft is re-absorbed into pre-synaptic neurons with only 10% bound to post-synaptic neurons.

Depression, treatment, side-effect Failure of serotonin messaging is currently regarded as the most likely cause of Depression. Traditional treatment blocks serotonin re-absorption (SSRI) increasing the amount of post-synaptic serotonin binding. Results in loss of serotonin.

Failure of serotonin messaging is currently regarded as the most likely cause of Depression.

Traditional treatment blocks serotonin re-absorption (SSRI) increasing the amount of post-synaptic serotonin binding.

Results in loss of serotonin.

Serotonin Messaging by transporting No serotonin loss in serotonin messaging Jung, C.H., Serotonin messaging mediated by 5-HR-channels not 5-HR-receptor, Nature , 2006, 20, 1159-1165 Jung, C.H., Total serotonin concentration unaffected in Depression type I, Nature , 2005, 20, 1159-1165 No serotonin loss in serotonin messaging 10% of serotonin released from pre-synaptic neurons is absorbed into post-synaptic neurons.

No serotonin loss in serotonin messaging

Jung, C.H., Serotonin messaging mediated by 5-HR-channels not 5-HR-receptor, Nature , 2006, 20, 1159-1165

Jung, C.H., Total serotonin concentration unaffected in Depression type I, Nature , 2005, 20, 1159-1165

No serotonin loss in serotonin messaging

10% of serotonin released from pre-synaptic neurons is absorbed into post-synaptic neurons.

Abnormal serotonin-concentration in Depression Low serotonin concentration in post-synaptic neurons. Jakobs, D.R., et al., Serotonin concentration involved in depression type I, Science , 2006, 21, 501-509 Fig3. Measured serotonin concentration in pre- and post - synap tic neurons for time point 5 and 20 in control group and depression (Drc-). The Figure shows that there is no lack of serotonin in the pre- synap tic neurons , yet absorbed serotonin levels in post-synap tic are too low .

Low serotonin concentration in post-synaptic neurons.

Jakobs, D.R., et al., Serotonin concentration involved in depression type I, Science , 2006, 21, 501-509

Normal number of HRCs No observable difference in concentration of HRCs in post-synaptic neurons. Jung, C.H. et al., SSRI induced 5-HR increase only a hack , Nature , 2006, 21, 180-185 Fig2. Flourescence images of pre - and post - synap tic neurons for the control group and depression (Drc-). The images show that the amount of 5-HR channels (red fluorescence) is not reduced in Drc-, yet the absorbed serotonin (green fluorescence) in the post-synap tic neurons is significantly reduced. Control Drc-

No observable difference in concentration of HRCs in post-synaptic neurons.

Correlation of Fsr9 with low serotonin absorption Fsr9 , responsible for the serotonin concentration in post-synaptic neurons. Fig2. Correlation between over expression of Fsr9 and reduced serotonin intake of post - synap tic neurons in depression (Drc-). Panel A : Fsr9 in Drc- is present in high concentrations very early in the time course. Panel B : The early onset of Fsr9 stops the absorption of serotonin into the post - synap tic neurons , resulting in an overall lower serotonin concentration. Chen, L.L. et al. ,The role of Fsr9 in Depression Type I , Int J Dev Neurosci, 2007, 22, 180-185

Fsr9 , responsible for the serotonin concentration in post-synaptic neurons.

F sr9 blocks 5-HR c h annels Fsr9 , adjust the serotonin concentration. Not in regulatory manner, but in physical manner Fig2. Flourescence images of pre - and post - synap tic neurons in depression (Drc-) for 5-HR C and Fsr 9. The images show the co-localization of Fsr 9 (green fluorescence) and 5-HRC (blue fluorescence) as yellow fluorescence. Chen, L.L. et al. , Co-localization of 5-HRC and Fsr9 suggest a new drug target for depression, Neurophysiology , 2007, 20

Fsr9 , adjust the serotonin concentration.

Not in regulatory manner, but in physical manner

Serotonin messaging - The full picture Jung, C.H. et al. , RNA interference of fsr9 - a new generation antidepressant, Nature , 2007, 23 Vesicle-mediated release licensed by Capsulution ®

Efficiency time 20 Jung, C.H. et al. , RNA interference of fsr9 - a new generation antidepressant, Nature , 2007, 23

Comparison Jung, C.H. et al. , The breakthrough in antidepressants, Nature , 2008, in submission actual serotonin loss no known Side effects short-term long-term Solution intensive neutral Biological resources weeks hours Onset SSRI reliF ®

The reliF ® Approach Fsr9-specific RNAi molecules are transported to serotonin absorbing synapses . Transport is mediated by glycosylation-pattern recognizing vesicles produced by Capsulution ® The constant delivery of RNAi molecules prevents the premature onset of Fsr9 expression . The normal absorption period of HRCs is restored. Leading to a healthy concentration of serotonin in the post - synap tic neurons , with no known side effects . Jung, C.H. et al. , RNA interference of fsr9 - a new generation antidepressant, Nature , 2007, 23

Fsr9-specific RNAi molecules are transported to serotonin absorbing synapses .

Transport is mediated by glycosylation-pattern recognizing vesicles produced by Capsulution ®

The constant delivery of RNAi molecules prevents the premature onset of Fsr9 expression .

The normal absorption period of HRCs is restored.

Leading to a healthy concentration of serotonin in the post - synap tic neurons , with no known side effects .

Overview Goal - Develop an effective, side-effect free drug to provide fast relief from depression. Motivation and Progress Dr. Andrew Ringsmuth Market analysis Financial overview IP Portfolio Pitch

Goal - Develop an effective, side-effect free drug to provide fast relief from depression.

Motivation and Progress Dr. Andrew Ringsmuth

Market analysis

Financial overview

IP Portfolio

Pitch

Market for reliF ® Depression affects 7-18% of the population (In USA, 14 million adults/yr diagnosed) Clinical depression is the leading cause of disability in North America Expected to become the second leading cause worldwide by 2020 (World Health Organization)

Depression affects 7-18% of the population (In USA, 14 million adults/yr diagnosed)

Clinical depression is the leading cause of disability in North America

Expected to become the second leading cause worldwide by 2020 (World Health Organization)

The existing world market (2006)* Antidepressant drugs (SSRIs, NRIs, MAOIs) US$17 billion Psychotherapy US$5.2 billion Electroconvulsive therapy US$120 million Other methods (e.g. acupuncture, hypnotherapy, meditation) Est. US$3.5 billion Total annual market value US$25.82 billion Projected market growth **: >5.2% by 2010 (> US$27.16 billion ) *World Health Organisation annual report 2006 **GlaxoSmithKline, 2006

Antidepressant drugs (SSRIs, NRIs, MAOIs)

US$17 billion

Psychotherapy

US$5.2 billion

Electroconvulsive therapy

US$120 million

Other methods (e.g. acupuncture, hypnotherapy, meditation)

Est. US$3.5 billion

Total annual market value US$25.82 billion

Projected market growth **: >5.2% by 2010 (> US$27.16 billion )

*World Health Organisation annual report 2006

**GlaxoSmithKline, 2006

The reliF ® advantage Problems with SSRIs (7 FDA approved, 87% of existing antidepressant market): Slow acting (upto 6-8wks. 55% of prescriptions accompany psychotherapeutic treatments) Unpredictable efficacy and side effects (Average sufferer trials 1 drug unsuccessfully + ) reliF Fast acting (same day) Shown to be effective in >97% cases where an SSRI is effective ++ No known side effects Predicted cost to consumer 5-15% above most popular SSRI ( Cymbalta ) Analysts predict price to be competitive + Davis, K. & James, P. (2006). ‘The efficacy of drug-based depression treatments’ . J. Neur. Psych. 131 (3): 496-507. ++ Jung, C.H. et al. , RNA interference of fsr9 - a new generation antidepressant, Nature , 2007, 23.

Problems with SSRIs (7 FDA approved, 87% of existing antidepressant market):

Slow acting (upto 6-8wks. 55% of prescriptions accompany psychotherapeutic treatments)

Unpredictable efficacy and side effects (Average sufferer trials 1 drug unsuccessfully + )

reliF

Fast acting (same day)

Shown to be effective in >97% cases where an SSRI is effective ++

No known side effects

Predicted cost to consumer

5-15% above most popular SSRI ( Cymbalta )

Analysts predict price to be competitive

+ Davis, K. & James, P. (2006). ‘The efficacy of drug-based depression treatments’ . J. Neur. Psych. 131 (3): 496-507.

++ Jung, C.H. et al. , RNA interference of fsr9 - a new generation antidepressant, Nature , 2007, 23.

Expanding market potential Evidence 1 to suggest that reliF technology is adaptable to other depression-associated neurotransmitters (targeted by other existing antidepressants) R&D costs for adaptation << potential market value 1 Jung, C.H. et al. , RNA interference of fsr9 - a new generation antidepressant, Nature , 2007, 23

Evidence 1 to suggest that reliF technology is adaptable to other depression-associated neurotransmitters (targeted by other existing antidepressants)

R&D costs for adaptation << potential market value

Investment opportunity Investment to complete Phase II (3-5 years): AUD $3.8 million (>$2.0 million startup + milestone payments) Benefits to investor during Phase II: 40% share in permON Position on board of directors permON exit strategy: Option 1: Licensing Initial licensing fee: ~AUD $25 million Worldwide royalties: 7-10% (subj. to neg.) Option 2: Sale Complete sale: >AUD $100 million Partial sale: Retain a part share in permON when reliF goes to market Investor return: Option 1: Initial licensing: ~AUD: $10 million 40% share in permON royalties (> USD $700 million in first year, assuming 5-10% share of SSRI market) Option 2: Complete sale: >AUD $40 million Partial sale: Return determined by share retained

Investment to complete Phase II (3-5 years):

AUD $3.8 million (>$2.0 million startup + milestone payments)

Benefits to investor during Phase II:

40% share in permON

Position on board of directors

permON exit strategy:

Option 1: Licensing

Initial licensing fee: ~AUD $25 million

Worldwide royalties: 7-10% (subj. to neg.)

Option 2: Sale

Complete sale: >AUD $100 million

Partial sale: Retain a part share in permON when reliF goes to market

Investor return:

Option 1:

Initial licensing: ~AUD: $10 million

40% share in permON royalties (> USD $700 million in first year, assuming 5-10%

share of SSRI market)

Option 2:

Complete sale: >AUD $40 million

Partial sale: Return determined by share retained

Overview Goal - Develop an effective, side-effect free drug to provide fast relief from depression. Motivation and Progress - Large demand and even growing market in the future. IP Portfolio Dr. Kimberly Wadsworth Pitch

Goal - Develop an effective, side-effect free drug to provide fast relief from depression.

Motivation and Progress - Large demand and even growing market in the future.

IP Portfolio Dr. Kimberly Wadsworth

Pitch

IP Portfolio Scientific discovery: Fsr9 discovered: March 2005 reliF ® works on Fsr9: December 2005 Provisional patent application filed in the USA: Fsr9: 13 June 2005 reliF ® : 7 January 2006 Publications: Jung, C.H., Total serotonin concentration unaffected in Depression type I, Nature , 2005, 20, 1159-1165 Jung, C.H., Serotonin messaging mediated by 5-HR-channels not 5-HR-receptor, Nature , 2006, 20, 1159-1165 Jakobs, D.R., et al., Serotonin concentration involved in depression type I, Science , 2006, 21, 501-509 Jung, C.H. et al., SSRI induced 5-HR increase only a hack , Nature , 2006, 21, 180-185 Chen, L.L. et al. ,The role of Fsr9 in Depression Type I , Int J Dev Neurosci, 2007, 22, 180-185 Chen, L.L. et al. , Co-localization of 5-HRC and Fsr9 suggest a new drug target for depression, Neurophysiology , 2007, 20 Jung, C.H. et al. , RNA interference of fsr9 - a new generation antidepressant, Nature , 2007, 23 Jung, C.H. et al. , The breakthrough in antidepressants, Nature , 2008, in submission

Scientific discovery:

Fsr9 discovered: March 2005

reliF ® works on Fsr9: December 2005

Provisional patent application filed in the USA:

Fsr9: 13 June 2005

reliF ® : 7 January 2006

Publications:

Jung, C.H., Total serotonin concentration unaffected in Depression type I, Nature , 2005, 20, 1159-1165

Jung, C.H., Serotonin messaging mediated by 5-HR-channels not 5-HR-receptor, Nature , 2006, 20, 1159-1165

Jakobs, D.R., et al., Serotonin concentration involved in depression type I, Science , 2006, 21, 501-509

Jung, C.H. et al., SSRI induced 5-HR increase only a hack , Nature , 2006, 21, 180-185

Chen, L.L. et al. ,The role of Fsr9 in Depression Type I , Int J Dev Neurosci, 2007, 22, 180-185

Chen, L.L. et al. , Co-localization of 5-HRC and Fsr9 suggest a new drug target for depression,

Neurophysiology , 2007, 20

Jung, C.H. et al. , RNA interference of fsr9 - a new generation antidepressant, Nature , 2007, 23

Jung, C.H. et al. , The breakthrough in antidepressants, Nature , 2008, in submission

IP Portfolio Formation of permON ® : 3 April 2006 PCT (Patent Cooperation Treaty) application filed: Fsr9: 12 June 2006 reliF ® : 6 January 2007 National phase entry: Fsr9 (13 December 2007 - 13 January 2008): Australia United States of America Europe Japan Canada Plans to enter national phase for reliF ® in same jurisdictions

Formation of permON ® : 3 April 2006

PCT (Patent Cooperation Treaty) application filed:

Fsr9: 12 June 2006

reliF ® : 6 January 2007

National phase entry:

Fsr9 (13 December 2007 - 13 January 2008):

Australia

United States of America

Europe

Japan

Canada

Plans to enter national phase for reliF ® in same jurisdictions

Trademarks and licensing Trademarks: reliF ® permON ® Licensing: Capsulution ® Obtained commercial license

Trademarks:

reliF ®

permON ®

Licensing:

Capsulution ®

Obtained commercial license

Pitch reliF ® is an effective, side-effect free drug to provide fast relief from depression. Large demand in an ever growing market. We have taken reliF ® to pre-clinical trials (proof of concept) For your $3.8 million, you will see a return of at least $10 million plus royalties.

reliF ® is an effective, side-effect free drug to provide fast relief from depression.

Large demand in an ever growing market.

We have taken reliF ® to pre-clinical trials (proof of concept)

For your $3.8 million, you will see a return of at least $10 million plus royalties.

Outside opinions of leading clinicians “ When depression becomes a small inconvenience, rather than the major impact on human society, we can look forward to a bright future and reliF ® is better suited than vicodin.” Dr. Gregory House “ reliF ® will be a major breakthrough in depression treatment.” Dr. Meredith Grey “ reliF ® and Aspirin, two man made miracles” Dr. Frank Campion

“ When depression becomes a small inconvenience, rather than the major impact on human society, we can look forward to a bright future and reliF ® is better suited than vicodin.”

Dr. Gregory House

“ reliF ® will be a major breakthrough in depression treatment.”

Dr. Meredith Grey

“ reliF ® and Aspirin, two man made miracles”

Dr. Frank Campion

Add a comment

Related presentations

Related pages

Relief – Wikipedia

Ein Relief [reˈli̯ɛf] ist eine künstlerische Darstellung, die sich plastisch vom Hintergrund abhebt, meist aus einer Fläche oder einem Körper heraus.
Read more

relief® Germany - relief® Germany ltd – Leichter Leben ...

relief® - Ein Leben ohne Nikotin. Um Rauchern den Ausstieg zu erleichtern setzt relief® auf eine bewährte Anwendung/Methode. Rauchen ist out - Aufhören ...
Read more

Relief (Geologie) – Wikipedia

Die Artikel Gelände und Relief (Geologie) überschneiden sich thematisch. Hilf mit, die Artikel besser voneinander abzugrenzen oder zusammenzuführen (→ ...
Read more

dict.cc Wörterbuch :: relief :: Deutsch-Englisch-Übersetzung

Englisch-Deutsch-Übersetzung für relief im Online-Wörterbuch dict.cc (Deutschwörterbuch).
Read more

dict.cc | Relief | Wörterbuch Englisch-Deutsch

Übersetzung für Relief im Englisch-Deutsch-Wörterbuch dict.cc.
Read more

Startseite: Islamic Relief Deutschland

Islamic Relief Humanitäre Organisation in Deutschland e. V. (IRD) ist eine deutsche Nichtregierungsorganisation und Partner von Islamic Relief Worldwide.
Read more

Relief Übersetzung Relief Definition auf TheFreeDictionary

Re·li·ẹf das [reˈli̯ɛf] kunst: aus einer Fläche herausgearbeitetes plastisches Kunstwerk das Relief über dem ...
Read more

Duden | Re­li­ef | Rechtschreibung, Bedeutung ...

Definition, Rechtschreibung, Synonyme und Grammatik von 'Relief' auf Duden online nachschlagen. Wörterbuch der deutschen Sprache.
Read more

Relief – Wiktionary

... Bei der Ausstellung wurde auch ein Relief des Mariannengrabens gezeigt. [3] Nach dem Grade des im Relief hervorstrebenden Materials unterscheidet man ...
Read more

Spende: Islamic Relief Deutschland

Islamic Relief hilft überall dort, wo Menschen unter bewaffneten Konflikten leiden oder auf der Flucht sind, wo Erdbeben, Überschwemmungen oder andere ...
Read more